Why the Time Course Can Change the Dose Decision
Two doses can look similar at one assessment and differ meaningfully over the full treatment course. A dose with a slower onset may eventually provide greater benefit but leave symptoms uncontrolled early. Another dose may produce a response that persists after treatment ends. Toxicity can also accumulate even when a measurement at the final visit appears acceptable. Dose selection should therefore compare predicted outcomes over the treatment and follow-up periods that matter to patients and clinicians.
This requires a defined treatment schedule, a time origin, and clinically relevant outcomes. The predictions are conditional on a model and its assumptions; they are not observations of what every individual will experience. The earlier material on sensitivity analysis for dose decisions is relevant because time-course predictions can depend strongly on uncertain rate parameters.
A dose decision should specify what is being optimized or constrained. Examples include reaching a minimum benefit by a specified day, maintaining benefit during treatment, limiting the maximum toxicity state, or minimizing accumulated toxicity over treatment and follow-up. The chosen time window is part of the decision: a model prediction for day 14 does not answer a question about control through day 28 or recovery after discontinuation.
First-Order Models for Onset and Persistence
A simple model for a delayed benefit \(B_d(t)\) at dose \(d\) is a first-order response approaching a dose-specific plateau \(B_{\infty,d}\). If treatment starts at time zero and benefit is zero at baseline, the model is
Here \(k_{\mathrm{on},d}>0\) is the onset rate, in inverse time, and \(B_{\infty,d}\) is the long-run benefit on the outcome's scale. Separating variables and integrating gives
The rate parameter determines how quickly the plateau is approached: the time constant is \(1/k_{\mathrm{on},d}\). This model assumes a constant plateau and a constant first-order approach to it under the specified regimen. It is a compact description, not a biological claim that every delayed response follows this exact mechanism.
Persistence after stopping can be represented separately. If the response at discontinuation time \(T\) is \(B_d(T)\), and its post-treatment decline is first-order, then for \(t\geq T\),
The decline parameter \(k_{\mathrm{off},d}\) is not necessarily the drug's elimination rate. It describes the decline of the modeled response. A slow response decline can reflect downstream pharmacology or disease dynamics, and it should not be interpreted as prolonged drug exposure unless the model specifically links the two.
Worked Example: A Slower-Onset Dose Overtakes Later
Hypothetical data. Consider two doses with benefit measured in points. Dose A has \(B_{\infty,A}=8\) points and \(k_{\mathrm{on},A}=0.10\) per day. Dose B has \(B_{\infty,B}=12\) points and \(k_{\mathrm{on},B}=0.04\) per day. Assume the first-order onset model applies under continuous treatment, and compare predictions on days 14 and 28.
For Dose A on day 14:
For Dose B on day 14:
At day 14, Dose A predicts the larger benefit. At day 28, the predictions are
Dose B has overtaken Dose A by day 28 because its higher plateau outweighs its slower onset at that time. The calculation does not establish that Dose B is preferable: the decision also depends on whether early benefit is essential, on safety, and on uncertainty in the parameters. It does establish that a single early endpoint could rank the doses differently from a later one.
Persistence During Follow-Up
When the response may continue after treatment ends, follow-up predictions belong in the dose comparison. The first-order decay model implies that after one time constant, \(1/k_{\mathrm{off}}\), the response remaining is \(e^{-1}\), or about 36.8%, of its value at discontinuation. This describes the modeled response, not necessarily a patient's probability of remaining a responder.
Worked Example: Comparing Residual Benefit After Stopping
Hypothetical data. Treatment stops on day 28. The modeled benefit at discontinuation is 7.514 points for Dose A and 8.085 points for Dose B. After stopping, the decline rates are \(k_{\mathrm{off},A}=0.10\) per day and \(k_{\mathrm{off},B}=0.25\) per day. Assume first-order response decay and predict benefit on day 35, seven days after stopping.
For Dose A, the decay factor over seven days is \(e^{-0.10(7)}=e^{-0.7}\approx0.496585\). Thus,
For Dose B, the factor is \(e^{-0.25(7)}=e^{-1.75}\approx0.173774\). Thus,
Dose B has the higher predicted benefit at discontinuation, but its faster modeled decline means Dose A predicts more residual benefit on day 35. These figures depend on both the response at stopping and the post-treatment decline rate. A comparison that reports only the day-28 response would miss that difference.
The follow-up horizon should be long enough to address the clinical question. If the decision concerns sustained benefit after a short course, a prediction immediately after stopping is insufficient. Conversely, extending follow-up indefinitely can overemphasize model behavior far beyond the observed data. Predictions should be tied to a prespecified, clinically justified period.
Representing Accumulating Toxicity
A toxicity state \(C_d(t)\) can be modeled as the balance between formation and removal. Under a constant dose-specific input rate \(r_d\) during treatment, a simple model is
Here \(r_d\) is the toxicity-state input per day and \(k_C>0\) is the first-order removal rate per day. Solving the differential equation gives
The toxicity state approaches \(r_d/k_C\) while dosing continues. If treatment stops at time \(T\), the model can set the input to zero; for \(t>T\), the state then declines as \(C_d(t)=C_d(T)e^{-k_C(t-T)}\). The state value at one time and its accumulated burden are different summaries. One possible cumulative measure over \(0\) to \(T\) is the area under the toxicity-state curve:
This integral has units of toxicity-state units multiplied by time. It is useful only if that scale and summary correspond to the clinical toxicity question. A maximum state, duration above a threshold, or probability of a clinically important event may be more relevant in other settings.
Worked Example: Balancing Efficacy and Cumulative Toxicity
Hypothetical data. For a 28-day treatment, suppose both doses exceed a prespecified minimum benefit of 7.0 points at day 28: Dose A predicts 7.5 points and Dose B predicts 8.1 points. For toxicity, assume \(k_C=0.02\) per day, with constant input rates \(r_A=0.08\) and \(r_B=0.13\) toxicity units per day. Suppose a toxicity state of 3.0 units is the maximum acceptable value. Use the state model above and compare both the day-28 state and the cumulative state burden through day 28.
The common factor is \(1-e^{-0.02(28)}=1-e^{-0.56}\approx0.428791\). For Dose A, \(r_A/k_C=0.08/0.02=4\), so
For Dose B, \(r_B/k_C=0.13/0.02=6.5\), so
Both predicted states are below the 3.0-unit limit. For cumulative burden, the common bracket in the integral is
Therefore, Dose A predicts \(4(6.56045)=26.24\) toxicity unit-days, while Dose B predicts \(6.5(6.56045)=42.64\) toxicity unit-days. Under the stated decision rule—meet the day-28 benefit minimum and then prefer the lower modeled cumulative burden—Dose A is favored. Dose B's additional predicted benefit is not required by that rule, and it comes with both a higher day-28 toxicity state and a greater cumulative burden. A different benefit target or utility trade-off could lead to a different choice.
Assumptions, Diagnostics, and Alternatives
Time-course comparisons are only as credible as their inputs. At minimum, the treatment schedule and time origin must be correctly represented, the outcome scale must be appropriate, and the model must describe the relevant observation period reasonably well. The simple examples assume fixed rate parameters and deterministic predictions. Real patients vary, measurements have error, and parameter estimates are uncertain; population-average predictions do not by themselves describe the distribution of individual outcomes.
Useful diagnostics include checking whether the observed trajectory has the shape the model predicts, whether residuals show systematic time patterns, and whether predictions differ materially when plausible onset, decline, or toxicity-removal rates are used. Sparse early measurements make onset rates difficult to distinguish from plateau size. Short follow-up makes slow response decay hard to estimate. Similarly, if toxicity is observed only at the final visit, a model may fit that endpoint while missing an earlier peak or prolonged time above a threshold. Adequate measurement timing is therefore part of the evidence needed to support the model.
The main alternatives answer different questions. A single-endpoint dose-response comparison is simpler when the endpoint time is clinically decisive and prior trajectories add little. A time-to-event analysis may be preferable when the clinically relevant outcome is the timing of a defined event. More mechanistic PK/PD models can link concentration, response turnover, and toxicity, but require suitable measurements and stronger structural assumptions. Flexible longitudinal models can describe observed trajectories with fewer mechanistic commitments, although extrapolation beyond observed times may be less reliable. These approaches are not interchangeable: the model should follow the decision question and the available data.
A common mistake is to select the dose with the largest response at one visit, or to treat an acceptable final toxicity measurement as proof that toxicity has not accumulated. The correction is to define the relevant time horizon and outcome summaries first, then compare predicted response and harm across that horizon, including follow-up when persistence or recovery matters. State clearly which quantities are observed, which are model-derived, and which decision rule turns predictions into a dose choice.
Check Your Understanding
Answer each question using the definitions and models in this tutorial. Solutions are included after the questions.
- In the delayed-onset model, what does \(1/k_{\mathrm{on}}\) represent, and what does it not represent?
- A response is 10 points at discontinuation and declines with \(k_{\mathrm{off}}=0.20\) per day. What does the first-order model predict seven days later?
- For a toxicity state with constant input \(r\), what are the long-run state and the condition that determines whether the state is increasing at a given time?
- Why can a final-visit toxicity measurement fail to summarize cumulative toxicity?
- Suppose two doses both satisfy a prespecified benefit minimum, but one has lower predicted cumulative toxicity burden. What additional assumptions or decision criteria are needed before selecting it?
Solutions. (1) \(1/k_{\mathrm{on}}\) is the model's onset time constant; it is the time scale of approach to the plateau, not the time to reach the plateau or the drug's elimination half-life. (2) \(10e^{-0.20(7)}=10e^{-1.4}\approx2.466\) points. (3) The long-run state under constant input is \(r/k_C\). The state increases when \(dC/dt=r-k_CC>0\), equivalently when \(C<r/k_C\). (4) It gives the state at one time, not the area accumulated over time, an earlier peak, or duration above a threshold. (5) The benefit minimum and toxicity summary must be clinically appropriate, model predictions sufficiently credible for the chosen horizon, and the decision rule must specify how remaining efficacy and harms are traded off; uncertainty and other relevant outcomes should also be considered.